146 related articles for article (PubMed ID: 31622099)
21. MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.
Improgo MR; Tesar B; Klitgaard JL; Magori-Cohen R; Yu L; Kasar S; Chaudhary D; Miao W; Fernandes SM; Hoang K; Westlin WF; Kim HT; Brown JR
Br J Haematol; 2019 Mar; 184(6):925-936. PubMed ID: 30537114
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with
Dlouhy I; Armengol M; Recasens-Zorzo C; Ribeiro ML; Pérez-Galán P; Bosch F; López-Guillermo A; Roué G
Haematologica; 2022 Dec; 107(12):2990. PubMed ID: 36453521
[No Abstract] [Full Text] [Related]
23. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
[TBL] [Abstract][Full Text] [Related]
24. Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.
Cumming IA; Degorce SL; Aagaard A; Braybrooke EL; Davies NL; Diène CR; Eatherton AJ; Felstead HR; Groombridge SD; Lenz EM; Li Y; Nai Y; Pearson S; Robb GR; Scott JS; Steward OR; Wu C; Xue Y; Zhang L; Zhang Y
Bioorg Med Chem; 2022 Jun; 63():116729. PubMed ID: 35439688
[TBL] [Abstract][Full Text] [Related]
25. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
26. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
27. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
28. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
Chaudhary D; Robinson S; Romero DL
J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
[TBL] [Abstract][Full Text] [Related]
30. Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4.
Wang Z; Sun D; Johnstone S; Cao Z; Gao X; Jaen JC; Liu J; Lively S; Miao S; Sudom A; Tomooka C; Walker NP; Wright M; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2015 Dec; 25(23):5546-50. PubMed ID: 26526214
[TBL] [Abstract][Full Text] [Related]
31. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
[TBL] [Abstract][Full Text] [Related]
32. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.
Staiger AM; Ott MM; Parmentier S; Rosenwald A; Ott G; Horn H; Griese EU
Br J Haematol; 2015 Oct; 171(1):145-8. PubMed ID: 25816840
[No Abstract] [Full Text] [Related]
33. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
[TBL] [Abstract][Full Text] [Related]
34. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
[TBL] [Abstract][Full Text] [Related]
35. Functional assessment of the mutational effects of human IRAK4 and MyD88 genes.
Yamamoto T; Tsutsumi N; Tochio H; Ohnishi H; Kubota K; Kato Z; Shirakawa M; Kondo N
Mol Immunol; 2014 Mar; 58(1):66-76. PubMed ID: 24316379
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with
Dlouhy I; Armengol M; Recasens-Zorzo C; Ribeiro ML; Pérez-Galán P; Bosch F; López-Guillermo A; Roué G
Haematologica; 2021 Oct; 106(10):2749-2753. PubMed ID: 33979991
[No Abstract] [Full Text] [Related]
37. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Wenglowsky S; Ren L; Grina J; Hansen JD; Laird ER; Moreno D; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Sturgis HL; Voegtli WC; Vigers G; Willis B; Mathieu S; Rudolph J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1923-7. PubMed ID: 24675381
[TBL] [Abstract][Full Text] [Related]
38. Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.
Fairhurst RA; Gerspacher M; Imbach-Weese P; Mah R; Caravatti G; Furet P; Fritsch C; Schnell C; Blanz J; Blasco F; Desrayaud S; Guthy DA; Knapp M; Arz D; Wirth J; Roehn-Carnemolla E; Luu VH
Bioorg Med Chem Lett; 2015 Sep; 25(17):3575-81. PubMed ID: 26199119
[TBL] [Abstract][Full Text] [Related]
39. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
[TBL] [Abstract][Full Text] [Related]
40. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
